Skip to main content
48°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bio-Path Holdings
(NQ:
BPTH
)
0.9800
+0.0700 (+7.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bio-Path Holdings
< Previous
1
2
3
4
5
6
7
Next >
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
October 10, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 09, 2024
Via
Benzinga
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
October 08, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Nasdaq Surges Over 1%; DocuSign Shares Spike Higher
October 08, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 08, 2024
Via
Benzinga
Crude Oil Falls Over 4%; US Trade Deficit Narrows In August
October 08, 2024
Via
Benzinga
Exposures
Fossil Fuels
US Stocks Edge Higher; PepsiCo Cuts 2024 Revenue Outlook
October 08, 2024
Via
Benzinga
ACHR, BPTH, PLUG, REGRF:
October 08, 2024
Leaders Report Latest Advances
Via
News Direct
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
October 08, 2024
Bio-Path is advancing its obesity treatment BP1001-A and completing trials for BP1002 in acute myeloid leukemia, targeting resistance mechanisms in treatment. Preclinical studies for obesity are set...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 08, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
October 03, 2024
Via
Benzinga
Bio-Path Holdings Announces Publication in Biomedicines
September 16, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 24
September 04, 2024
Dallas, Texas--(Newsfile Corp. - September 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path...
Via
Newsfile
Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
September 02, 2024
Via
Benzinga
What Happened With Bio-Path Stock Today?
August 21, 2024
Bio-Path shares ended Wednesday's session slightly higher after the company provided an update from its ongoing Phase 1/1b clinical trial of BP1001-A.
Via
Benzinga
Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid Tumors
August 21, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Bio-Path Holdings Reports Second Quarter 2024 Financial Results
August 15, 2024
Conference Call to be Held Today at 8:30 A.M. ET
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
BPTH Stock Earnings: Bio-Path Holdings Beats EPS for Q2 2024
August 14, 2024
BPTH stock results show that Bio-Path Holdings beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024
August 08, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Bio-Path Holdings Provides Clinical Update and Expansion Plans
July 08, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
June 18, 2024
It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Tuesday morning!
Via
InvestorPlace
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
June 17, 2024
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
June 17, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Onsemi Layoffs 2024: What to Know as Onsemi Cuts 1,000 Jobs
June 14, 2024
Onsemi layoffs are a hot topic on Friday after the company announced plans to cut jobs and close down some of its sites on weak demand.
Via
InvestorPlace
Topics
Workforce
Exposures
Layoff
Why Bank of America Thinks Hasbro (HAS) Stock Can Gain 40% From Here
June 14, 2024
Hasbro stock is up on Friday with a price target increase and rating upgrade for HAS shares from Bank of America analsyts.
Via
InvestorPlace
Why Is Bio-Path (BPTH) Stock Up 20% Today?
June 14, 2024
Bio-Path stock is up on Friday with heavy trading of NPTH shares after the company posited positive interim data from a Phase 2 study.
Via
InvestorPlace
Why Bio-Path Stock Is Climbing Today
June 14, 2024
Bio-Path Holdings shares are trading higher Friday after the company announced interim results from its Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
June 14, 2024
Via
Benzinga
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
June 14, 2024
Encore Presentation Highlights Positive Results from Interim Analysis Demonstrating Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.